Loading…
OS Therapies Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -59.9% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $1.40 | $4.28 | |
| EPS | -$0.98 | -$1.28 |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| APLMApollomics Inc. | $26.60 | — | — | — | -1305.37% | $77.04M |
| RNXTRenovoRx, Inc. | $1.67 | — | 8.4x | — | -125.23% | $75.37M |
| NRXSNeuraxis, INC | $6.00 | — | 11.1x | — | -139.76% | $75.35M |
| GANXGain Therapeutics, Inc. | $1.77 |
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
Company description provided by Yahoo Finance.
| — |
| 6.8x |
| — |
| -268.30% |
| $77.25M |
| CINGCingulate Inc. | $5.33 | — | 3.2x | — | -198.74% | $77.44M |
| LONALeonaBio, Inc. | $7.94 | — | 2.2x | — | -431.39% | $74.81M |